Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, an increase of 128.0% from the January 15th total of 535,000 shares. Based on an average daily volume of 595,600 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.7% of the company's shares are sold short.
Tiziana Life Sciences Stock Up 7.0 %
NASDAQ TLSA traded up $0.05 on Monday, reaching $0.79. The stock had a trading volume of 348,594 shares, compared to its average volume of 1,207,392. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74. The stock has a fifty day moving average price of $0.77 and a two-hundred day moving average price of $0.92.
Institutional Trading of Tiziana Life Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bison Wealth LLC purchased a new stake in Tiziana Life Sciences in the fourth quarter valued at approximately $30,000. Zhang Financial LLC increased its position in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company's stock worth $65,000 after acquiring an additional 23,800 shares during the period. Geode Capital Management LLC increased its position in shares of Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after acquiring an additional 27,041 shares during the period. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Tiziana Life Sciences during the third quarter worth $864,000.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Articles
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
